April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Combined Therapy For Subretinal Neovascularzation Secondary To Idiopatic Macular Teleangectasia Type 2
Author Affiliations & Notes
  • Clara Battista
    Oculistica, Ospedale Civile S Donato Arezzo, Arezzo, Italy
  • Sandro Nardoni
    Oculistica, Ospedale Civile S Donato Arezzo, Arezzo, Italy
  • Paola Slanisca
    Oculistica, Ospedale Civile S Donato Arezzo, Arezzo, Italy
  • Andrea Romani
    Oculistica, Ospedale Civile S Donato Arezzo, Arezzo, Italy
  • Footnotes
    Commercial Relationships  Clara Battista, None; Sandro Nardoni, None; Paola Slanisca, None; Andrea Romani, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4527. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Clara Battista, Sandro Nardoni, Paola Slanisca, Andrea Romani; Combined Therapy For Subretinal Neovascularzation Secondary To Idiopatic Macular Teleangectasia Type 2. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4527.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the results of the combination therapy with intravitreal bevacizumab and photodynamic therapy (PDT) in a retrospective interventional case series of 10 treatment-naive eyes affected by subretinal neovascularization (SRNV) secondary to idiopatic macular teleangectasia type 2 (MT2).

Methods: : All patients underwent a best corrected visual acuity (BCVA) measurement by ETDRS chart, FAG, high speed ICG with stereo images before and after treatment. Intravitreal bevacizumab (1mg/0.04ml) was injected and followed within 10 days by PDT. The antiangiogenic therapy was repeated if useful, associated with PDT only if necessary.

Results: : Mean follow-up time was 23 months (range from 12 to 35). Mean BCVA at baseline was 20/50 (range from 20/25 to 20/125) and increased at last visit to 20/40 (range from 20/20 to 20/200). All eyes showed stabilization or improvement in BCVA except one and absence of leakage on FAG. Mean PDT number was 1.3 and mean intravitreal injection number was 2.6.

Conclusions: : Combination therapy appears logical because of the different and complementary active mechanisms of bevacizumab and PDT that may be efficacious in the treatment of SRNV secondary to MT2.

Keywords: macula/fovea • retinal neovascularization • degenerations/dystrophies 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×